Rigaku and Emerald Bio Announce Strategic Alliance
News Aug 01, 2013
Rigaku has acquired the crystallization reagent and consumable business, including the popular Wizard™ screens, from Emerald Bio, a world leader in protein science. In addition, both companies have agreed to work together to develop new products and solutions in the growing field of protein science.
“The addition of these consumables and screening kits is another step in creating a single contact point for our instrumentation customers, improving the efficiency of their workflow,” stated Catherine Klein, president of Rigaku Americas Corporation’s Life Sciences Division. “Further, having Emerald Bio as a development partner and customer will help ensure that we are at the forefront of new product needs in protein science.”
“Having Rigaku, the world leading protein crystallography instrumentation company, as a development partner is ideal for Emerald,” said Johan Pontin, CEO of Emerald Bio. “While we focus on our growing consulting solutions business,” said George Abe, president of Emerald Bio, “we can rely on Rigaku to support our own internal workflow needs and we now have a partner to build integrated solutions, including software, for our mutual customers.”
Researchers have solved the structures of the cancer-promoting enzymes USP25 and USP28, and identified significant differences in their activities. This knowledge provides the molecular basis for the development of new and highly specific anti-cancer drugs, with a low risk of side-effects.READ MORE